Preclinical development and first-in-human study of KA2507, a selective and potent inhibitor of histone deacetylase 6, for patients with refractory solid tumors

Apostolia M. Tsimberidou, Philip A. Beer, Carrie A. Cartwright, Cara Haymaker, Henry H. Vo, Simin Kiany, Alexander R.L. Cecil, James Dow, Kemal Haque, Franck A. Silva, Lucy Coe, Helen Berryman, Elisabeth A. Bone, Graciela M. Nogueras-Gonzalez, David Vining, Hilary McElwaine-Johnn, Ignacio I. Wistuba

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Fingerprint

Dive into the research topics of 'Preclinical development and first-in-human study of KA2507, a selective and potent inhibitor of histone deacetylase 6, for patients with refractory solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences